<DOC>
	<DOCNO>NCT00436436</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , O ( 6 ) -benzylguanine temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study side effect well give O ( 6 ) -benzylguanine together temozolomide work treat patient glioblastoma multiforme respond previous temozolomide radiation therapy .</brief_summary>
	<brief_title>O ( 6 ) -Benzylguanine Temozolomide Treating Patients With Glioblastoma Multiforme That Did Not Respond Previous Temozolomide Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity O6-benzylguanine temozolomide patient temozolomide-resistant methylguanine methyltransferase-positive -negative glioblastoma multiforme previously treat radiotherapy . - Determine , preliminarily , toxicity regimen patient . OUTLINE : Patients receive O6-benzylguanine intravenous ( IV ) 1 hour oral temozolomide daily day 1-5 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically least 6 month . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme ( GBM ) , include follow : Small large cell GBM Gliosarcoma Temozolomideresistant disease , define follow : Unequivocal evidence tumor progression receive adjuvant temozolomide therapy 5 consecutive day every 28 day ≥ 2 course Must fail prior radiotherapy Progression must document MRI ( stable steroid dose ≥ 5 day ) ≥ 12 week completion radiotherapy Must paraffinembedded tissue block ≥ 4 unstained paraffinembedded microscope slide available diagnosis PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 8 week White blood cell ( WBC ) ≥ 3,000/mm ( ³ ) Absolute neutrophil count ≥ 1,500/mm ( ³ ) Platelet count ≥ 100,000/mm ( ³ ) Hemoglobin ≥ 10 g/dL ( transfusion allow ) Aspartate aminotransaminase ( AST ) &lt; 2 time upper limit normal ( ULN ) Bilirubin &lt; 2 time ULN Creatinine &lt; 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min No significant medical illness , opinion investigator , would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant active cardiac , hepatic , renal , psychiatric disease No known active malignancy except nonmelanoma skin cancer carcinoma situ cervix No active infection require intravenous ( IV ) antibiotics No disease would obscure toxicity alter drug metabolism PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior temozolomide Prior resection recurrent progressive tumor allow follow criterion meet : Recovered prior surgery Residual disease resection recurrent tumor compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) ( stable steroid dose ≥ 5 day ) ≤ 96 hour OR ≥ 4 week surgery At least 12 week since prior radiotherapy No prior therapy ( i.e. , polifeprosan 20 carmustine implant [ Gliadel wafer ] nitrosoureas ) No concurrent chemotherapy , radiotherapy , immunotherapy , investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>